Telemedicine-supported Management for Acute Ischemic Stroke
NCT ID: NCT07302971
Last Updated: 2026-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
2400 participants
INTERVENTIONAL
2026-02-02
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study focused on patients with acute ischemic stroke who sought treatment at basic-level hospitals, aiming to investigate the efficacy and safety of treating acute ischemic stroke with telemedicine-supported management. Hospitals assigned to the experimental group received remote consultation guidance, quality control and professional training from expert teams at leading stroke centers, China National Center for Neurological Disorders. Hospitals in the control group did not receive telemedicine-supported management.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Pre-hospital and In-hospital Iv-tPA Stroke Treatment
NCT02358772
Application of Standardized Green Channel Treatment System for Ischemic Stroke in Xi 'an
NCT05424978
Tele-Stroke: Prehospital Identification of Patients With Suspected Stroke Using Onsite Mobile Telemedicine - Feasibility
NCT03370094
Chinese Acute Ischemic Stroke Treatment Outcome Registry
NCT02470624
Remote Ischemic Conditioning Paired With Endovascular Treatment for Acute Ischemic Stroke
NCT03045055
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Telemedicine-Supported Group
Receive remote guidance from expert stroke centers for treatment of patients with intravenous thrombolysis, along with quality control for standardized workflow support, and professional training.
Telemedicine-Supported Management
Receive round-the-clock 7×24h remote consultation guidance from expert teams at leading stroke centers, covering patient triage and initial assessment, thrombolysis decision-making, and treatment guidance. Undergo quality control for standardized workflow implementation, and professional training.
Standard Treatment Group without Telemedicine-Supported Management
Control-group patients will receive routine stroke care at their primary care hospitals, with no remote consultation, study-related quality control, or extra training. Care will follow the hospitals' usual protocols, including emergency assessment, neurological evaluation, imaging, and intravenous thrombolysis. Hospitals may continue their regular stroke-related training during the study to reflect real-world practice.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Telemedicine-Supported Management
Receive round-the-clock 7×24h remote consultation guidance from expert teams at leading stroke centers, covering patient triage and initial assessment, thrombolysis decision-making, and treatment guidance. Undergo quality control for standardized workflow implementation, and professional training.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Equipped with an emergency department and neurology ward capable of admitting stroke patients.
3. Equipped with CT and/or MRI capable of diagnosing AIS.
4. Equipped with intravenous thrombolytic drugs for acute ischemic stroke.
1. Age ≥ 18 years.
2. Diagnosed with acute ischemic stroke.
3. CT/MRI confirms absence of intracerebral hemorrhage.
4. Onset of stroke symptoms ≤ 4.5 hours.
5. pre-stroke mRS score ≤1.
6. Informed consent obtained from patient or their legal representative.
Exclusion Criteria
2. Currently participating in other clinical trials that may interfere with this trial.
1. Presence of contraindications for intravenous thrombolysis according to AHA/ASA guidelines
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Capital Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ji Xunming,MD,PhD
Professor of Neurology, Xuanwu Hospital, Capital Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xuanwu Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TOGETHER
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.